Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SI-B003 alone, BL-B01D1 + SI-B003, and BL-B01D1 + PD-1 antibody in advanced gastrointestinal cancers
CTR20232531Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SI-B003, izalontamab brengitecan, PD-1 Monoclonal Antibody in esophageal cancer, gastric cancer (GC), colorectal cancer (CRC), gastrointestinal system tumor, sponsored by Biokin Pharmaceutical. Started Nov 2023; status: active.
02
Drugs
SI-B003izalontamab brengitecanPD-1 Monoclonal Antibody
03
Conditions
esophageal cancergastric cancer (GC)colorectal cancer (CRC)gastrointestinal system tumor
Beyond the preview
Go deeper on CTR20232531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232531.